4.1 Review

Microphysiological systems in early stage drug development: Perspectives on current applications and future impact

期刊

JOURNAL OF TOXICOLOGICAL SCIENCES
卷 46, 期 3, 页码 99-114

出版社

JAPANESE SOC TOXICOLOGICAL SCIENCES
DOI: 10.2131/jts.46.99

关键词

Microphysiological systems; Complex in vitro models; Organ-chips; Drug safety

资金

  1. Japan Agency for Medical Research and Development (AMED)
  2. Kyoto University Nano Technology Hub

向作者/读者索取更多资源

MPS have the potential to improve drug development and reduce the use of animals in research, but face challenges in adoption and require collaboration between organizations and regulators to address limitations and establish reproducibility.
Microphysiological systems (MPS) arc making advances to provide more standardized and predictive physiologically relevant responses to test articles in living tissues and organ systems. The excitement surrounding the potential of MPS to better predict human responses to medicines and improving clinical translation is overshadowed by their relatively slow adoption by the pharmaceutical industry and regulators. Collaboration between multiorganizational consortia and regulators is necessary to build an understanding of the strengths and limitations of MPS models and closing the current gaps. Here, we review some of the advances in MPS research, focusing on liver, intestine, vascular system, kidney and lung and present examples highlighting the context of use for these systems. For MPS to gain a foothold in drug development, they must have added value over existing approaches. Ideally, the application of MPS will augment in vivo studies and reduce the use of animals via tiered screening with less reliance on exploratory toxicology studies to screen compounds. Because MPS support multiple cell types (e.g. primary or stem-cell derived cells) and organ systems, identifying when MPS are more appropriate than simple 2D in vitro models for understanding physiological responses to test articles is necessary. Once identified, MPS models require qualification for that specific context of use and must be reproducible to allow future validation. Ultimately, the challenges of balancing complexity with reproducibility will inform the promise of advancing the MPS field and are critical for realization of the goal to reduce, refine and replace (3Rs) the use of animals in nonclinical research.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据